NASDAQ:CALC CalciMedica (CALC) Stock Price, News & Analysis $2.74 -0.17 (-5.84%) Closing price 08/8/2025 03:59 PM EasternExtended Trading$2.72 -0.03 (-0.91%) As of 08/8/2025 07:09 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About CalciMedica Stock (NASDAQ:CALC) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get CalciMedica alerts:Sign Up Key Stats Today's Range$2.66▼$2.9050-Day Range$1.43▼$4.2052-Week Range$1.42▼$5.97Volume25,237 shsAverage Volume147,843 shsMarket Capitalization$38.28 millionP/E RatioN/ADividend YieldN/APrice Target$16.00Consensus RatingBuy Company Overview CalciMedica, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for illnesses caused by inflammatory and immunologic processes and direct cellular damage. The company's lead product candidate comprises Auxora, an intravenous formulated small molecule calcium release-activated (CRAC) channel inhibitors, which is in phase 2 clinical trials for the treatment of acute pancreatitis, asparaginase induced pancreatic toxicity, and acute kidney injury, as well as severe COVID-19 pneumonia. It also develops CM6336, an oral CRAC channel inhibitors for chronic inflammatory indications; and Auxora, for the treatment of acute ulcerative colitis and allergic asthma. The company is based in La Jolla, California. Read More CalciMedica Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks60th Percentile Overall ScoreCALC MarketRank™: CalciMedica scored higher than 60% of companies evaluated by MarketBeat, and ranked 391st out of 923 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingCalciMedica has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageCalciMedica has only been the subject of 1 research reports in the past 90 days.Read more about CalciMedica's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for CalciMedica are expected to decrease in the coming year, from ($2.21) to ($2.24) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of CalciMedica is -1.76, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of CalciMedica is -1.76, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCalciMedica has a P/B Ratio of 2.56. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about CalciMedica's valuation and earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted1.43% of the float of CalciMedica has been sold short.Short Interest Ratio / Days to CoverCalciMedica has a short interest ratio ("days to cover") of 1.5, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in CalciMedica has recently decreased by 15.26%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldCalciMedica does not currently pay a dividend.Dividend GrowthCalciMedica does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted1.43% of the float of CalciMedica has been sold short.Short Interest Ratio / Days to CoverCalciMedica has a short interest ratio ("days to cover") of 1.5, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in CalciMedica has recently decreased by 15.26%, indicating that investor sentiment is improving significantly. News and Social Media1.1 / 5News SentimentN/A Search Interest3 people have searched for CALC on MarketBeat in the last 30 days. This is an increase of 50% compared to the previous 30 days.MarketBeat Follows12 people have added CalciMedica to their MarketBeat watchlist in the last 30 days. Company Ownership3.3 / 5Insider TradingAcquiring Shares Insider Buying vs. Insider SellingIn the past three months, CalciMedica insiders have bought 2,136.71% more of their company's stock than they have sold. Specifically, they have bought $81,640.00 in company stock and sold $3,650.00 in company stock.Percentage Held by Insiders41.55% of the stock of CalciMedica is held by insiders. A high percentage of insider ownership can be a sign of company health.Read more about CalciMedica's insider trading history. Receive CALC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for CalciMedica and its competitors with MarketBeat's FREE daily newsletter. Email Address CALC Stock News HeadlinesCalciMedica Inc. (NASDAQ:CALC) Director Robert N. Wilson Acquires 4,500 SharesJuly 19, 2025 | insidertrades.comEric W. Roberts Purchases 6,500 Shares of CalciMedica Inc. (NASDAQ:CALC) StockJuly 17, 2025 | insidertrades.comA new rule goes live in July — and the banks are quietly crushing itA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Street and the Big Banks… It gives them the green light to treat a certain tangible asset as equivalent to cold, hard cash. Not stocks. Not real estate. And definitely not the U.S. dollar. We're talking about something they don't want you to notice — because the fewer people who act on this, the better it is for them. | American Alternative (Ad)CalciMedica Inc. (CALC) Stock Price Today - WSJJuly 18, 2025 | wsj.comCalciMedica chief scientific officer Stauderman buys $1,850 in stockJuly 8, 2025 | investing.comCalciMedica to Participate in the H.C. Wainwright 4th Annual Kidney Virtual ConferenceJuly 8, 2025 | prnewswire.comCalcimedica (CALC) director Roberts buys $6k in sharesJune 29, 2025 | investing.comCalciMedica, Inc. (CALC) stock price, news, quote & history - Yahoo FinanceJune 27, 2025 | au.finance.yahoo.comSee More Headlines CALC Stock Analysis - Frequently Asked Questions How have CALC shares performed this year? CalciMedica's stock was trading at $3.54 at the beginning of the year. Since then, CALC stock has decreased by 22.6% and is now trading at $2.74. How were CalciMedica's earnings last quarter? CalciMedica Inc. (NASDAQ:CALC) posted its quarterly earnings data on Wednesday, May, 14th. The company reported ($0.36) earnings per share for the quarter, topping analysts' consensus estimates of ($0.43) by $0.07. Who are CalciMedica's major shareholders? Top institutional investors of CalciMedica include Envestnet Asset Management Inc. (0.67%), 180 Wealth Advisors LLC (0.36%), Atria Investments Inc (0.32%) and Cetera Investment Advisers (0.26%). Insiders that own company stock include Sanderling Venture Partners Vi, Robert N Wilson, Eric W Roberts, Kenneth A Stauderman, A Rachel Leheny and Stephen Bardin. View institutional ownership trends. How do I buy shares of CalciMedica? Shares of CALC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of CalciMedica own? Based on aggregate information from My MarketBeat watchlists, some other companies that CalciMedica investors own include Zomedica (ZOM), Jumia Technologies (JMIA), Nano Dimension (NNDM), AST SpaceMobile (ASTS), NIO (NIO), Bakkt (BKKT) and Castor Maritime (CTRM). Company Calendar Last Earnings5/14/2025Today8/09/2025Next Earnings (Estimated)8/11/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:CALC CIK1534133 Webwww.graybug.vision Phone858-952-5500FaxN/AEmployees30Year FoundedN/APrice Target and Rating Average Price Target for CalciMedica$16.00 High Price Target$16.00 Low Price Target$16.00 Potential Upside/Downside+483.9%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Trailing Twelve Months)($1.56) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$13.70 million Net MarginsN/A Pretax MarginN/A Return on Equity-171.81% Return on Assets-100.43% Debt Debt-to-Equity Ratio0.79 Current Ratio5.66 Quick Ratio5.66 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.07 per share Price / Book2.56Miscellaneous Outstanding Shares13,970,000Free Float8,167,000Market Cap$38.28 million OptionableNo Data Beta1.33 Social Links Reduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.Get This Free Report This page (NASDAQ:CALC) was last updated on 8/9/2025 by MarketBeat.com Staff From Our PartnersYour blueprint for crypto wealthMark August 12th on your calendar. 27 of crypto's most successful minds are about to reveal everything…Crypto 101 Media | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredHIDDEN IN THE BOOK OF GENESIS…“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredCrypto Income (almost instantly)How would you like to collect a small percentage of the $4 billion changing hands daily in the crypto market? ...Awesomely, LLC | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CalciMedica Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share CalciMedica With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.